First Hawaiian Bank’s Lexicon Pharmaceuticals LXRX Stock Holding History

First Hawaiian Bank’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-100	Closed	-$1K	–	1197
2019 Q1	$1K	Hold	100	–	–	﹤0.01%	1676
2018 Q4	$1K	Hold	100	–	–	﹤0.01%	1773
2018 Q3	$1K	Buy	+100	New	+$1.15K	﹤0.01%	1800

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

First Hawaiian Bank's LXRX Position: Q2 2019 in Review

First Hawaiian Bank sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2019, closing a stake of 100 shares — an estimated $1K sold.

First Hawaiian Bank first reported a position in LXRX in Q3 2018 and held it in 3 quarters. The position peaked at $1K in Q1 2019. 109 funds tracked by Wall St. Rank hold LXRX as of Q2 2019.

First Hawaiian Bank reported no remaining Lexicon Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
First Hawaiian Bank sold 100 Lexicon Pharmaceuticals shares in Q2 2019, an estimated $1K.
First Hawaiian Bank first reported a position in Lexicon Pharmaceuticals in Q3 2018 and held it in 3 quarters.
First Hawaiian Bank's Lexicon Pharmaceuticals position peaked at $1K in Q1 2019.
109 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2019.

Based on First Hawaiian Bank's 13F filing for Q2 2019, filed 15 Jul 2019.